GSMA Partnership Programme Expands to Create the Largest IoT Community in Asia Pacific
25.9.2019 08:00:00 EEST | Business Wire | Press release
The GSMA APAC IoT Partnership Programme has expanded to include more than thirty mobile operators making it the largest IoT community in the Asia Pacific region (APAC), the GSMA announced today. The programme brings operators and their partners together including developers, manufacturers and system integrators to share best practice, discuss challenges and progress updates on the development of IoT across the region. The initiative has seen 7 operators open 9 new IoT Labs in the region to help develop new IoT-based solutions. APAC has the largest IoT market in the world and is expected to reach 11 billion connections by 2025 and be worth $386 billion, according to GSMA Intelligence.
“The programme has doubled in size in less than a year and that is testament to the support, engagement and commitment of the mobile operator community who are collaborating closely with their partners to lead the expansion and growth of IoT across the region,” said Julian Gorman, Head of Asia Pacific, GSMA. “This is now the largest cross-regional IoT community in the world and we are already seeing the impact it is having in terms of the development of new solutions. I look forward to seeing how it continues to grow in the coming years.”
APAC Impact
Since launch in October 2018, the APAC IoT Partnership Programme has had an instant impact throughout the region, encouraging more than 120 companies such as IoT developers or solutions companies to work with operators. The programme has also supported the development, design and funding of 9 new IoT Labs throughout the region that is encouraging the development of new products. The IoT labs are a key mechanism for collaboration, encouraging the joint development of new use cases, services and applications that are enabling IoT innovations to be effectively deployed. The programme has also held a series of workshops exploring key industry topics such as Mobile IoT, AI and 5G as well as offered capacity building for local regulators and stakeholders and provided best practice support.
Mobile IoT Experiencing Fastest Global Growth
The APAC region is the fastest growing IoT market in the world, accounting for approximately 40 per cent of the total global IoT spend in 2018. Global Low Power Wide Area (LPWA) or Mobile IoT network connections have also been driven primarily by the APAC region accounting for nearly 97% of all NB-IoT connections according to ABI Research. Mobile IoT networks are being merged into 5G standards to support low latency, massive IoT and large bandwidth. Thirty-seven of the world’s 119 Mobile IoT networks are also deployed in Asia Pacific across 15 countries. China in particular has been a key market in driving early adoption, accounting for 40 per cent of the global LPWA connections in 2018.
IoT @ GSMA Mobile 360 – Digital Societies
The GSMA IoT programme will host a number of different activities at GSMA M360 – Digital Societies held in Kuala Lumpur on Thursday 26 September 2019. This includes the APAC IoT Innovation Summit which provides attendees with insight from mobile operators and their partners on the latest developments in Mobile IoT. There will also be a number of interactive demos showcasing Mobile IoT, 5G, AI, Big Data Analytics, Blockchain and Drones at IoT Expo – Connected APAC. This will include hands on demonstrations from key industry verticals such as agriculture, aviation and retail and host smart home, smart traffic and smart poultry solutions. For further information, please go here: https://www.gsma.com/iot/events/m360-apac-iot-summit/#expo
The Birth of Beyond Connectivity
The GSMA will launch the ‘Beyond Connectivity’ campaign at Mobile 360 – Digital Societies. Beyond Connectivity describes how mobile operators are delivering innovation and transformative solutions to customers across big data, machine learning, analytics, edge computing and distributed ledger technologies and delivering beyond just data connectivity. To find out more, please go to: www.gsma.com/BeyondConnectivity
-ENDS-
Notes to Editors
- Operators include Axiata Group (Axiata Robi, Celcom, Dialog Axiata, Ncell, Smart Axiata, XL Axiata and Xpand), Indosat Ooredoo, Jazz, M1, Maxis, Mobitel, Smartfren, Singtel Group (Singtel, Optus), StarHub, Telenor Group (Digi, DTAC, Grameenphone, Telenor Connexion, Telenor Myanmar, Telenor Pakistan), Telstra, TM ONE, True, Rakuten, Viettel Group (Metfone, Mytel, Unitel, Viettel), Vodafone Idea
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators and nearly 400 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.
For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190924005080/en/
Contact information
For the GSMA
Gearóid Cashman
+44 79 7679 0169
GCashman@webershandwick.com
GSMA Press Office
pressoffice@gsma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
